NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free ZURA Stock Alerts $4.39 +0.77 (+21.27%) (As of 11:35 AM ET) Add Compare Share Share Today's Range$3.68▼$4.6450-Day Range$2.05▼$4.0152-Week Range$2.00▼$14.00Volume334,189 shsAverage Volume279,633 shsMarket Capitalization$189.17 millionP/E RatioN/ADividend YieldN/APrice Target$16.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Zura Bio alerts: Email Address Zura Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside318.4% Upside$16.40 Price TargetShort InterestHealthy2.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 11 Articles This WeekInsider TradingAcquiring Shares$534,998 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.00) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector247th out of 908 stocksBiological Products, Except Diagnostic Industry31st out of 147 stocks 3.6 Analyst's Opinion Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.27% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 31.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZURA. Previous Next 3.4 News and Social Media Coverage News SentimentZura Bio has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Zura Bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $534,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($1.00) to ($1.26) per share.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> About Zura Bio Stock (NASDAQ:ZURA)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More ZURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZURA Stock News HeadlinesApril 25, 2024 | insidertrades.comKiran Nistala Buys 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) StockApril 26, 2024 | americanbankingnews.comKiran Nistala Acquires 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) StockApril 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 26, 2024 | americanbankingnews.comMichael Howell Buys 7,987 Shares of Zura Bio Limited (NASDAQ:ZURA) StockApril 26, 2024 | americanbankingnews.comAmit Munshi Buys 159,744 Shares of Zura Bio Limited (NASDAQ:ZURA) StockApril 25, 2024 | finance.yahoo.comDirector Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)April 20, 2024 | msn.comZura Bio stock jumps on plans to raise $112.5M in private financingApril 18, 2024 | markets.businessinsider.comZura Bio Announces Private Placement Of $112 MLn Of Class A Shares; Stock UpApril 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 18, 2024 | marketwatch.comZura Bio Shares Rise 16% After Private Placement Valued at $112.5MApril 18, 2024 | finance.yahoo.comZura Bio Announces Oversubscribed $112.5 Million Private PlacementApril 8, 2024 | businesswire.comZura Bio Announces Robert Lisicki as CEO and DirectorApril 3, 2024 | benzinga.comZura Bio Stock (NASDAQ:ZURA), Analyst Ratings, Price Targets, PredictionsApril 2, 2024 | finance.yahoo.comInsider Buyers At Zura Bio Recover Some Losses, But Still Down US$165kMarch 31, 2024 | finance.yahoo.comZura Bio Ltd (ZURA) Reports Full Year 2023 Financial Results Amidst Leadership TransitionMarch 28, 2024 | businesswire.comZura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerMarch 4, 2024 | businesswire.comZura Bio Announces Participation at March ConferencesFebruary 14, 2024 | finance.yahoo.comWe're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn RateFebruary 3, 2024 | msn.comZura Bio Issues Regulation FD Disclosure StatementFebruary 2, 2024 | finance.yahoo.comZura Bio Announces Participation at February Investor ConferencesJanuary 8, 2024 | msn.comZura Bio appoints industry veteran Robert Lisicki as President and COOJanuary 8, 2024 | finance.yahoo.comZura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMOJanuary 3, 2024 | finance.yahoo.comZura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology SummitDecember 4, 2023 | finance.yahoo.comZura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in BangkokNovember 14, 2023 | finance.yahoo.comZura Bio Appoints Arnout Ploos van Amstel to its Board of DirectorsNovember 13, 2023 | msn.comZura Bio GAAP EPS of -$0.18November 13, 2023 | finance.yahoo.comZura Bio Reports Third Quarter 2023 Financial Results and Recent Business HighlightsSee More Headlines Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$16.40 High Stock Price Target$22.00 Low Stock Price Target$10.00 Potential Upside/Downside+353.0%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-82.30% Return on Assets-66.71% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book1.96Miscellaneous Outstanding Shares43,094,000Free Float36,285,000Market Cap$156.00 million OptionableNot Optionable Beta0.55 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David BradyHead of Business DevelopmentDr. Someit Sidhu M.D. (Age 34)Founder, CEO & Director Mr. Robert Lisicki (Age 56)President & COO Mr. Verender S. Badial (Age 52)Chief Financial Officer Dr. Gary Whale Ph.D. (Age 50)Chief Technology Officer Dr. Michael D. Howell Ph.D. (Age 46)Chief Scientific Officer & Head of Translational Science Ms. Kimberly Ann Davis (Age 56)Chief Legal Officer & Secretary Ms. Theresa Lowry (Age 50)Chief Human Resources Officer Dr. Kiran Nistala MBBS (Age 51)Ph.D., Chief Medical Officer & Head of Development More ExecutivesKey CompetitorsCellectisNASDAQ:CLLSMolecular PartnersNASDAQ:MOLNScilexNASDAQ:SCLXDBV TechnologiesNASDAQ:DBVTAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsAmit MunshiBought 159,744 shares on 4/22/2024Total: $499,998.72 ($3.13/share)Michael HowellBought 7,987 shares on 4/22/2024Total: $24,999.31 ($3.13/share)Kiran NistalaBought 3,195 shares on 4/22/2024Total: $10,000.35 ($3.13/share)Forefront Analytics LLCBought 6,765 shares on 2/15/2024Ownership: 0.049%Armistice Capital LLCBought 244,000 shares on 2/13/2024Ownership: 4.233%View All Insider TransactionsView All Institutional Transactions ZURA Stock Analysis - Frequently Asked Questions Should I buy or sell Zura Bio stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZURA shares. View ZURA analyst ratings or view top-rated stocks. What is Zura Bio's stock price target for 2024? 5 brokerages have issued 12-month price objectives for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $22.00. On average, they predict the company's stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 318.4% from the stock's current price. View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts. How have ZURA shares performed in 2024? Zura Bio's stock was trading at $4.67 at the beginning of the year. Since then, ZURA shares have decreased by 16.1% and is now trading at $3.92. View the best growth stocks for 2024 here. Are investors shorting Zura Bio? Zura Bio saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 428,400 shares, a decrease of 31.8% from the March 31st total of 628,300 shares. Based on an average trading volume of 295,200 shares, the short-interest ratio is presently 1.5 days. Currently, 2.3% of the company's stock are sold short. View Zura Bio's Short Interest. When is Zura Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ZURA earnings forecast. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) released its earnings results on Monday, November, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZURA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
